CN114746445A - 抑制或激活γδT细胞的方法 - Google Patents

抑制或激活γδT细胞的方法 Download PDF

Info

Publication number
CN114746445A
CN114746445A CN202080058667.0A CN202080058667A CN114746445A CN 114746445 A CN114746445 A CN 114746445A CN 202080058667 A CN202080058667 A CN 202080058667A CN 114746445 A CN114746445 A CN 114746445A
Authority
CN
China
Prior art keywords
btn2a1
cells
antagonist
cell
tcr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080058667.0A
Other languages
English (en)
Chinese (zh)
Inventor
A·贝伦
J·希邦
M·R·考特尔
T·S·富尔福德
D·I·格弗雷
A·哈梅特
S·奥斯鲁斯卡
C·帕诺西斯
A·P·乌德里希
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Melbourne
CSL Innovation Pty Ltd
Olivia Newton John Cancer Research Institute
Original Assignee
University of Melbourne
CSL Innovation Pty Ltd
Olivia Newton John Cancer Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019902308A external-priority patent/AU2019902308A0/en
Application filed by University of Melbourne, CSL Innovation Pty Ltd, Olivia Newton John Cancer Research Institute filed Critical University of Melbourne
Publication of CN114746445A publication Critical patent/CN114746445A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
CN202080058667.0A 2019-06-28 2020-06-26 抑制或激活γδT细胞的方法 Pending CN114746445A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
AU2019902308A AU2019902308A0 (en) 2019-06-28 Method of inhibiting or activating gamma delta t cells
AU2019902308 2019-06-28
AU2019904771A AU2019904771A0 (en) 2019-12-17 Method of inhibiting or activating gamma delta t cells
AU2019904773 2019-12-17
AU2019904771 2019-12-17
AU2019904773A AU2019904773A0 (en) 2019-12-17 Method of inhibiting or activating gamma delta t cells
PCT/AU2020/050662 WO2020257871A1 (en) 2019-06-28 2020-06-26 Method of inhibiting or activating gamma delta t cells

Publications (1)

Publication Number Publication Date
CN114746445A true CN114746445A (zh) 2022-07-12

Family

ID=74059614

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080058667.0A Pending CN114746445A (zh) 2019-06-28 2020-06-26 抑制或激活γδT细胞的方法

Country Status (8)

Country Link
US (1) US20220273713A1 (https=)
EP (1) EP3990496A4 (https=)
JP (2) JP2022539753A (https=)
KR (1) KR20220100567A (https=)
CN (1) CN114746445A (https=)
AU (1) AU2020301813A1 (https=)
CA (1) CA3144755A1 (https=)
WO (1) WO2020257871A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025031287A1 (zh) * 2023-08-04 2025-02-13 江苏恒瑞医药股份有限公司 Btn3a结合蛋白及其医药用途
WO2025082418A1 (zh) * 2023-10-18 2025-04-24 苏州沙砾生物科技有限公司 一种鉴定靶标的方法及其应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022109110A1 (en) * 2020-11-19 2022-05-27 Shattuck Labs, Inc. Methods of identifying gamma delta t cell-modulating agents
US20250179144A1 (en) * 2021-12-09 2025-06-05 The University Of Melbourne Modified Butyrophilin and Butyrophilin Complexes
EP4638472A1 (en) * 2022-12-19 2025-10-29 UMC Utrecht Holding B.V. Btn2a1 binding peptide
WO2025045192A1 (en) * 2023-08-31 2025-03-06 Biosion Inc. Antibodies binding btn3a1 and uses thereof
WO2025064752A1 (en) * 2023-09-20 2025-03-27 La Jolla Institute For Immunology Human anti-sars-cov-2 spike (s) antibodies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108778314A (zh) * 2015-12-16 2018-11-09 沃尔特及伊莱萨霍尔医学研究院 Nk细胞中对细胞因子诱导的sh2蛋白的抑制
CN109195987A (zh) * 2016-02-29 2019-01-11 Ose免疫疗法 针对IL7受体胞外域的α链的非拮抗性抗体及其在癌症治疗中的应用
WO2019057933A1 (en) * 2017-09-21 2019-03-28 Imcheck Therapeutics Sas ANTIBODIES HAVING SPECIFICITY FOR BTN2 AND USES THEREOF

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0717101D0 (en) * 2007-09-03 2007-10-10 Cambridge Entpr Ltd Tumour marker
JP2016540046A (ja) * 2013-11-29 2016-12-22 シーエスエル、リミテッド ガンの治療方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108778314A (zh) * 2015-12-16 2018-11-09 沃尔特及伊莱萨霍尔医学研究院 Nk细胞中对细胞因子诱导的sh2蛋白的抑制
CN109195987A (zh) * 2016-02-29 2019-01-11 Ose免疫疗法 针对IL7受体胞外域的α链的非拮抗性抗体及其在癌症治疗中的应用
WO2019057933A1 (en) * 2017-09-21 2019-03-28 Imcheck Therapeutics Sas ANTIBODIES HAVING SPECIFICITY FOR BTN2 AND USES THEREOF

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025031287A1 (zh) * 2023-08-04 2025-02-13 江苏恒瑞医药股份有限公司 Btn3a结合蛋白及其医药用途
WO2025082418A1 (zh) * 2023-10-18 2025-04-24 苏州沙砾生物科技有限公司 一种鉴定靶标的方法及其应用

Also Published As

Publication number Publication date
AU2020301813A1 (en) 2022-01-27
WO2020257871A1 (en) 2020-12-30
KR20220100567A (ko) 2022-07-15
EP3990496A1 (en) 2022-05-04
US20220273713A1 (en) 2022-09-01
JP2025090566A (ja) 2025-06-17
EP3990496A4 (en) 2023-08-09
CA3144755A1 (en) 2020-12-30
JP2022539753A (ja) 2022-09-13

Similar Documents

Publication Publication Date Title
US12234286B2 (en) Anti-TIGIT antibodies and their use as therapeutics and diagnostics
CN114746445A (zh) 抑制或激活γδT细胞的方法
KR20210138574A (ko) Dll3 표적화 키메라 항원 수용체 및 결합제
JP7022067B2 (ja) Ｆｏｘｐ３由来のペプチドに特異的なｔ細胞受容体様抗体
TW201734046A (zh) 抗體和使用彼之方法
CN114174346B (zh) 抗hk2嵌合抗原受体(car)
JP2019534710A (ja) インターロイキン２に結合する抗体およびその使用
US11919953B2 (en) TIGIT and CD112R blockade
JP2022512875A (ja) 抗体製剤
CN113698492A (zh) 人间皮素嵌合抗原受体及其用途
CN115175940A (zh) Lilrb3抗体分子及其用途
RU2855103C1 (ru) Молекулы антитела к LILRB3 и их применение
RU2822366C2 (ru) Химерные антигенные рецепторы и связывающие агенты, нацеленные на dll3
WO2023137161A1 (en) Triple blockade of tigit, cd112r, and pd-l1
HK40070619A (en) Anti-hk2 chimeric antigen receptor (car)
HK40074599A (zh) Lilrb3抗体分子及其用途
HK40031598B (zh) 抗tigit抗体及其作为治疗和诊断的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220712

WD01 Invention patent application deemed withdrawn after publication